

Alvotech and DKSH extend partnership in Asia

25 September 2020 | News

Strategic partnership to commercialize six new biosimilar product candidates for the Asian markets



Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, on 22 Sep 2020 announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.

In March 2020, the companies announced its exclusive partnership agreement for AVT02, an adalimumab biosimilar, a leading drug indicated for the treatment of several autoimmune diseases. The collaboration includes the following markets: Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan. These biosimilar candidates' brand values are estimated around US\$1.5 billion in annual sales in the Asia Pacific region, according to IQVIA data.

The partnership accelerates the introduction of high quality biosimilar to patients in Asia. In the last twelve months, Alvotech has made very important strategic partnership agreements with leading regional and global industry players including: Teva in the U.S., Stada in Europe, JAMP in Canada, Yas Holding in the Middle East and Fuji Pharma in Japan.

"The partnership is designed to accelerate improved patient access for high quality biosimilar medicines in the Asian biosimilar industry." says Mark Levick, CEO of Alvotech.

"The extended partnership with Alvotech demonstrates our commitment to bringing high-quality medical products to Asian patients and enriching their lives. At DKSH, we believe biosimilars offer a tremendous opportunity to enhance the standard of

care in several disease areas across the Asian markets," says Bijay Singh, Global Head of Business Unit Healthcare, DKSH.